New Veeva Pulse findings show congresses and
early-career experts have the strongest influence on patient
outcomes
PLEASANTON, Calif., July 25,
2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today
revealed that targeted pre-launch scientific outreach maximizes
medical affairs teams' impact on treatment adoption in the latest
Veeva Pulse Field Trends Report. The analysis shows biopharmas
investing in pre-launch scientific activities and prioritizing
congresses gain 40% faster treatment adoption than those that
invested less. Early-career experts are also more open to digital
engagement and four times more likely to start patients on a new
treatment.
Healthcare professionals (HCPs) are turning to biopharmas to
help distill rapidly evolving scientific evidence around new
innovative medicines and complex diseases. By focusing pre-launch
activity around clinical guidelines, publications, and congresses
with a new group of stakeholders, medical affairs teams can reach
key HCPs to improve treatment decisions.
"Gone are the days when medical could just focus on the top-tier
scientific thought leaders," said Angela
Smart, director of global medical excellence and operations
at ADVANZ PHARMA. "The range of stakeholders has broadened, and
it's imperative to expand our engagement strategies beyond
traditional experts."
The latest analysis from Veeva Pulse finds that:
- Targeted pre-launch scientific activities speed treatment
adoption: By engaging key experts at congresses, helping
develop clinical guidelines, and securing coverage in publications
before launch, companies see 40% faster treatment adoption than
those that invest less in this outreach. This demonstrates that
more resources for medical teams during this stage can boost launch
success.
- Congress activity has the strongest influence on clinical
decisions: Higher investment in pre-launch congress activities
has the most influence on treatment after approval. Congresses, and
the digital discussions that follow, help increase scientific
awareness and drive impactful medical conversations more than
investment in clinical guidelines and publications.
- Engaging early-career HCPs increases new treatment
uptake: These digitally-savvy emerging experts are four times
more likely to start patients on a new treatment. They are also
five times more likely to speak at congresses, 11 times more likely
to engage digitally, and seven times more likely to get
published.
"As HCPs gain an increasing amount of information to understand
complex new medicines across channels, effectively communicating
scientific evidence before launch can make all the difference,"
said Dan Rizzo, vice president of
business consulting at Veeva. "By investing in different types
of scientific outreach and engaging newer experts during this
crucial window, medical teams can drive greater impact and faster
treatment adoption."
About the Veeva Pulse Field Trends Report
Analyzing
over 600 million HCP interactions and activities annually from more
than 80% of commercial biopharma field teams worldwide,
the Veeva Pulse Field Trends Report is the largest
industry benchmark of its kind on HCP engagement. The analysis
compiles real-time transactional data recorded in Veeva
CRM and Veeva data products to deliver a view of engagement
activity across life sciences. Indexed by Veeva quarterly, the data
will help companies effectively and accurately benchmark
performance to set the right, actionable goals for continued growth
and impact.
Additional Information
To download a copy of the Veeva
Pulse Field Trends Report, visit: veeva.com/FieldTrends
Learn more about Veeva Business
Consulting: veeva.com/BusinessConsulting
Connect with Veeva on
LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information,
visit veeva.com.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and services
and the expected results or benefits from use of our products and
services. These statements are based on our current expectations.
Actual results could differ materially from those provided in this
release and we have no obligation to update such statements. There
are numerous risks that have the potential to negatively impact our
results, including the risks and uncertainties disclosed in our
filing on Form 10-Q for the period ended April 30, 2024, which you can find here (a
summary of risks which may impact our business can be found on
pages 35 and 36), and in our subsequent SEC filings, which you can
access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/targeted-pre-launch-scientific-outreach-drives-40-faster-treatment-adoption-302206400.html
SOURCE Veeva Systems